Your browser doesn't support javascript.
loading
Effects of a Therapeutic Interchange Between Branded and Generic Inhaled Therapy on Chronic Obstructive Pulmonary Disease.
Acharya, Rucha B; Joseph, Tina; Moreau, Cynthia; Hale, Genevieve; Perez, Alexandra; Rosario, Elaina.
Afiliação
  • Acharya RB; 1Nova Southeastern University, Fort Lauderdale, Florida.
  • Joseph T; 1Nova Southeastern University, Fort Lauderdale, Florida.
  • Moreau C; 1Nova Southeastern University, Fort Lauderdale, Florida.
  • Hale G; 2Nova Southeastern University, Palm Beach, Florida.
  • Perez A; 1Nova Southeastern University, Fort Lauderdale, Florida.
  • Rosario E; 3Baptist Health South Florida, Miami, Florida.
Sr Care Pharm ; 36(12): 687-692, 2021 Dec 01.
Article em En | MEDLINE | ID: mdl-34861909
Objective To evaluate the difference in the occurrence of chronic obstructive pulmonary disease (COPD) exacerbations six months preconversion compared with six months postconversion from the branded inhaled corticosteroid/long-acting beta 2-agonist inhalers to the generic fluticasone/salmeterol inhalers. Design Retrospective cohort study using a six-month pre-/post-test design Setting Three primary care offices within a Management Service Organization (MSO) in South Florida. Patients, Participants Patients were included in the study if they had a diagnosis of COPD (in electronic medical record [EMR]), were at least 18 years of age, were under the care of a provider at one of the three primary care clinics within an MSO, and were switched from a branded ICS/LABA inhaler to a generic ICS/LABA inhaler between May 2019 and February 2020. This study included a total of 22 patients. Interventions Not applicable; this was a retrospective chart review. Main Outcome Measure The prevalence of COPD exacerbations leading to hospitalizations, emergency room visits, urgent care visits, or clinic visits. Results In this study, 10 (45.5%) patients experienced at least one exacerbation while on generic inhaler therapy compared with four (18.2%) patients while on branded inhaler therapy (P = 0.05). Those on a generic inhaler were 3.8 times more likely to have a COPD exacerbation. Conclusion While changing patients from branded to generic inhalers may be appealing because of the potential benefits in cost-reduction, the results of this study conclude that the inhaler switch may lead to increased exacerbations. Prescribers need to be aware of potential complications that may be related to a therapeutic interchange.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Broncodilatadores / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Broncodilatadores / Doença Pulmonar Obstrutiva Crônica Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article